缺血性腦卒中患者血清VILIP-1水平與疾病嚴(yán)重程度及預(yù)后的相關(guān)性研究
發(fā)布時(shí)間：2018-07-18 11:05
【摘要】：目的:探討缺血性腦卒中患者血清VILIP-1水平與疾病嚴(yán)重程度及預(yù)后的相關(guān)性。方法:收集延邊地區(qū)缺血性腦卒中患者108例,同期年齡、性別相匹配的對(duì)照組共103例,按照NIHSS評(píng)分量表對(duì)缺血性腦卒中患者在入院時(shí)進(jìn)行神經(jīng)功能缺損評(píng)分,嚴(yán)重程度分為輕、中和重型,按改良Rankin量表將患者預(yù)后分為完全無(wú)癥狀組、未見(jiàn)明顯殘障組、輕度殘障組、中度殘障組、中重度殘障組。酶聯(lián)免疫吸附法(ELISA)檢測(cè)兩組受試者入院時(shí)血清VILIP-1濃度含量。結(jié)果:(1)不同性別、年齡段卒中組及對(duì)照組組間比較血清VILIP-1水平無(wú)顯著性差異,缺血性腦卒中組VILIP-1水平明顯高于對(duì)照組(4.23±2.56ng/ml vs.3.03±1.90ng/ml,P0.001);缺血性腦卒中兩性患者中血清VILIP-1水平含量均高于對(duì)照組。(2)NIHSS評(píng)分為輕、中、重型三組的血清VILIP-1水平分別為(3.42±1.63、6.31±1.80、11.17±1.14ng/ml,P0.001),其中之間任意兩組的水平均數(shù)都具有統(tǒng)計(jì)學(xué)意義,且隨著NIHSS評(píng)分的逐漸增高,缺血性腦卒中組血清VILIP-1水平濃度也隨之增高;(3)短期預(yù)后的結(jié)果顯示Rankin量表評(píng)分的各組間的血清VILIP-1水平之間具有統(tǒng)計(jì)學(xué)差異(P0.05),中重度殘障組血清VILIP-1水平明顯高于完全無(wú)癥狀組、未見(jiàn)明顯殘障組、輕度殘障組、中度殘障組(P0.05)。隨著IS患者預(yù)后評(píng)分越高,患者血清VILIP-1水平也逐漸增加。(4)多因素Logistic回歸分析表明調(diào)整了 HCY、CRP、血糖等相關(guān)影響預(yù)后的因素后,VILIP-1水平仍是影響缺血性腦卒中預(yù)后的獨(dú)立危險(xiǎn)因素。結(jié)論:(1)血清VILIP-1可作為診斷缺血性腦卒中的參考指標(biāo),并可預(yù)測(cè)缺血性腦卒中的嚴(yán)重程度。(2)血清VILIP-1是影響缺血性腦卒中患者預(yù)后的獨(dú)立危險(xiǎn)因素,可預(yù)測(cè)缺血性腦卒中患者的短期預(yù)后。
[Abstract]:Objective: to investigate the correlation between serum VILIP-1 level and severity and prognosis of ischemic stroke patients. Methods: 108 patients with ischemic stroke in Yanbian area and 103 controls with matched age and sex were collected. According to NIHSS score scale, neurological deficit scores were scored on admission. According to the modified Rankin scale, the patients were divided into asymptomatic group, no significant disability group, mild disability group, moderate and severe disability group. Serum levels of VILIP-1 were measured by enzyme linked immunosorbent assay (Elisa). Results: (1) there was no significant difference in serum VILIP-1 levels between stroke group and control group in different sex, age group and control group. The level of VILIP-1 in ischemic stroke group was significantly higher than that in control group (4.23 鹵2.56ng/ml vs.3.03 鹵1.90 ng / ml P0.001), and the level of VILIP-1 in both sexes of ischemic stroke was higher than that in control group. (2) NIHSS score was mild and moderate. The serum levels of VILIP-1 in the three severe groups were (3.42 鹵1.63V 6.31 鹵1.80 鹵11.17 鹵1.14ng / ml P0.001) respectively. The mean water levels in any two groups were statistically significant, and with the increasing of NIHSS score, The level of VILIP-1 in patients with ischemic stroke was also increased. (3) the results of short-term prognosis showed that the levels of VILIP-1 in patients with moderate and severe disability were significantly higher than those in asymptomatic patients (P0.05), and the results of short-term prognosis showed that the levels of VILIP-1 in the groups with Rankin scale score were significantly higher than those in the asymptomatic group. No obvious disability group, mild disability group, moderate disability group (P0.05). The higher the prognosis score of is patients, the higher the level of serum VILIP-1. (4) the multivariate logistic regression analysis showed that adjusted HCYT CRP, blood glucose and other related prognostic factors, VILIP-1 level was still an independent risk factor for the prognosis of ischemic stroke. Conclusion: (1) Serum VILIP-1 can be used as a reference index for the diagnosis of ischemic stroke and can predict the severity of ischemic stroke. (2) Serum VILIP-1 is an independent risk factor for the prognosis of patients with ischemic stroke. It can predict the short-term prognosis of ischemic stroke patients.
【學(xué)位授予單位】：延邊大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R743.3
本文編號(hào)：2131711
[Abstract]:Objective: to investigate the correlation between serum VILIP-1 level and severity and prognosis of ischemic stroke patients. Methods: 108 patients with ischemic stroke in Yanbian area and 103 controls with matched age and sex were collected. According to NIHSS score scale, neurological deficit scores were scored on admission. According to the modified Rankin scale, the patients were divided into asymptomatic group, no significant disability group, mild disability group, moderate and severe disability group. Serum levels of VILIP-1 were measured by enzyme linked immunosorbent assay (Elisa). Results: (1) there was no significant difference in serum VILIP-1 levels between stroke group and control group in different sex, age group and control group. The level of VILIP-1 in ischemic stroke group was significantly higher than that in control group (4.23 鹵2.56ng/ml vs.3.03 鹵1.90 ng / ml P0.001), and the level of VILIP-1 in both sexes of ischemic stroke was higher than that in control group. (2) NIHSS score was mild and moderate. The serum levels of VILIP-1 in the three severe groups were (3.42 鹵1.63V 6.31 鹵1.80 鹵11.17 鹵1.14ng / ml P0.001) respectively. The mean water levels in any two groups were statistically significant, and with the increasing of NIHSS score, The level of VILIP-1 in patients with ischemic stroke was also increased. (3) the results of short-term prognosis showed that the levels of VILIP-1 in patients with moderate and severe disability were significantly higher than those in asymptomatic patients (P0.05), and the results of short-term prognosis showed that the levels of VILIP-1 in the groups with Rankin scale score were significantly higher than those in the asymptomatic group. No obvious disability group, mild disability group, moderate disability group (P0.05). The higher the prognosis score of is patients, the higher the level of serum VILIP-1. (4) the multivariate logistic regression analysis showed that adjusted HCYT CRP, blood glucose and other related prognostic factors, VILIP-1 level was still an independent risk factor for the prognosis of ischemic stroke. Conclusion: (1) Serum VILIP-1 can be used as a reference index for the diagnosis of ischemic stroke and can predict the severity of ischemic stroke. (2) Serum VILIP-1 is an independent risk factor for the prognosis of patients with ischemic stroke. It can predict the short-term prognosis of ischemic stroke patients.
【學(xué)位授予單位】：延邊大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R743.3
【參考文獻(xiàn)】
相關(guān)期刊論文 前8條
1 劉佳琪;楊春曉;;缺血性腦卒中側(cè)支循環(huán)的研究進(jìn)展[J];中風(fēng)與神經(jīng)疾病雜志;2016年07期
2 方向楠;秦彥文;岳衛(wèi)東;;內(nèi)質(zhì)網(wǎng)應(yīng)激與缺血性腦血管病的研究進(jìn)展[J];中華老年心腦血管病雜志;2016年04期
3 王媛媛;竇志杰;;低氧誘導(dǎo)因子-1α對(duì)缺血性腦卒中嚴(yán)重程度和預(yù)后的影響[J];承德醫(yī)學(xué)院學(xué)報(bào);2015年02期
4 李斌;安中平;朱延霞;王濤;;血清視錐蛋白樣蛋白-1及其他因素與缺血性卒中后認(rèn)知障礙的相關(guān)性[J];中國(guó)慢性病預(yù)防與控制;2014年06期
5 周震;王雪巖;王坤;王凱;張玉蓮;;開(kāi)放翼腭動(dòng)脈改良制備大鼠自體血栓腦梗死模型比較[J];中國(guó)比較醫(yī)學(xué)雜志;2014年09期
6 劉曉麗;張秀芝;蔡軍;孫長(zhǎng)義;滑世軒;姜曉峰;;VILIP-1在早期缺血性腦卒中的臨床診斷價(jià)值[J];中國(guó)衛(wèi)生檢驗(yàn)雜志;2014年15期
7 閆睿;初桂蘭;;血清神經(jīng)特異性烯醇化酶和視椎蛋白樣蛋白1水平對(duì)新生大鼠缺氧缺血性腦病的診斷價(jià)值[J];中國(guó)循證兒科雜志;2013年04期
8 費(fèi)娜;許麗珍;;鈣離子拮抗劑對(duì)帕金森病的神經(jīng)保護(hù)作用[J];中國(guó)誤診學(xué)雜志;2006年07期
，本文編號(hào)：2131711
本文鏈接：http://sikaile.net/yixuelunwen/shenjingyixue/2131711.html
最近更新
教材專(zhuān)著
